FYN and Alzheimer disease: Elevated CK1 activity leads to the excessive activation of GSK3β and CDK5, and the former further triggers Fyn activation, exacerbating neuronal excitotoxicity and neural network function, and ultimately contributing to neurodegeneration in AD.